Table 1: Toll-like receptor 9 agonists in clinical trials for cancer

From: Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

AgentCompanyTumor typeStage of development
PF-3512676 (formerly CPG 7909)PfizerBreast cancerPhase I/II
  CLLPhase I
  CTCLPhase I
  MelanomaPhase II
  NHLPhase I/II
 GlaxoSmithKlineNSCLCaPhase III
  RCCPhase I
ISS 1018DynavaxCRCPhase I
  NHLPhase II
IMO-2055IderaRCCPhase I
  Refractory solid tumorsPhase I/II
CpG-28University of ParisGlioblastomaPhase II
  1. Abbreviations: CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; CTCL, cutaneous T-cell lymphoma; NHL, non-Hodgkin's lymphoma; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.
  2. aClinical development in combination with chemotherapy has been discontinued.